Device Approved to Prevent Second Strokes in Certain Heart PatientsLast Updated: October 28, 2016.
FRIDAY, Oct. 28, 2016 (HealthDay News) -- The Amplatzer PFO Occluder device has been approved by the U.S. Food and Drug Administration to prevent another stroke among people who had at least one prior stroke involving a PFO (patent foramen avale).
A PFO is a small hole in the heart that could allow passage of a blood clot.
Up to 30 percent of Americans have a PFO, the FDA explained in a news release. The condition typically causes no health issues and doesn't require treatment.
However, in a small number of cases, the PFO provides "a path for a blood clot to travel to the brain where it [blocks] a blood vessel resulting in a stroke," the agency added.
The new device is inserted via a catheter in a leg vein and is advanced to the heart.
It was FDA approved nearly a decade ago, but its manufacturer withdrew the application for approval after the agency told the manufacturer that more than 4,000 people could be eligible for the device, making the device ineligible for the agency's humanitarian device exemption.
The new approval followed clinical testing of the device's safety and effectiveness among more than 900 participants, aged 18 to 60 years. Those who used the device plus blood-thinning medication were 50 percent less likely to have a new stroke, compared with those who took blood-thinning medication alone, the FDA said.
Potential side effects of the device include heart injury, irregular heart rate or blood clot at the implant site. People with abnormal connections between the heart's chambers or in whom unusual cardiovascular anatomy might inhibit the device's implantation shouldn't use the device, the FDA said.
The device is produced by St Jude Medical, based in Plymouth, Minn.
To learn more, visit the FDA.
|Previous: Nearly 3 Percent of U.S. Adults Have Weakened Immunity: Study||Next: Researchers: We Found Area of Brain That Responds to Placebo|
Reader comments on this article are listed below. Review our comments policy.